Literature DB >> 17005698

Murine model for dengue virus-induced lethal disease with increased vascular permeability.

Sujan Shresta1, Kristin L Sharar, Daniil M Prigozhin, P Robert Beatty, Eva Harris.   

Abstract

Lack of an appropriate animal model for dengue virus (DEN), which causes dengue fever and dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS), has impeded characterization of the mechanisms underlying the disease pathogenesis. The cardinal feature of DHF/DSS, the severe form of DEN infection, is increased vascular permeability. To develop a murine model that is more relevant to DHF/DSS, a novel DEN strain, D2S10, was generated by alternately passaging a non-mouse-adapted DEN strain between mosquito cells and mice, thereby mimicking the natural transmission cycle of the virus between mosquitoes and humans. After infection with D2S10, mice lacking interferon receptors died early without manifesting signs of paralysis, carried infectious virus in both non-neuronal and neuronal tissues, and exhibited signs of increased vascular permeability. In contrast, mice infected with the parental DEN strain developed paralysis at late times after infection, contained detectable levels of virus only in the central nervous system, and displayed normal vascular permeability. In the mice infected with D2S10, but not the parental DEN strain, significant levels of serum tumor necrosis factor alpha (TNF-alpha) were produced, and the neutralization of TNF-alpha activity prevented early death of D2S10-infected mice. Sequence analysis comparing D2S10 to its parental strain implicated a conserved region of amino acid residues in the envelope protein as a possible source for the D2S10 phenotype. These results demonstrate that D2S10 causes a more relevant disease in mice and that TNF-alpha may be one of several key mediators of severe DEN-induced disease in mice. This report represents a significant advance in animal models for severe DEN disease, and it begins to provide mechanistic insights into DEN-induced disease in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005698      PMCID: PMC1617308          DOI: 10.1128/JVI.00062-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population.

Authors:  Marco Vignuzzi; Jeffrey K Stone; Jamie J Arnold; Craig E Cameron; Raul Andino
Journal:  Nature       Date:  2005-12-04       Impact factor: 49.962

2.  Infection enhancement of dengue type 2 virus in the U-937 human monocyte cell line by antibodies to flavivirus cross-reactive determinants.

Authors:  W E Brandt; J M McCown; M K Gentry; P K Russell
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

3.  Antibody-enhanced dengue virus infection in primate leukocytes.

Authors:  S B Halstead; E J O'Rourke
Journal:  Nature       Date:  1977-02-24       Impact factor: 49.962

4.  Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection.

Authors:  Alena Atrasheuskaya; Peter Petzelbauer; Terry M Fredeking; George Ignatyev
Journal:  FEMS Immunol Med Microbiol       Date:  2003-01-21

Review 5.  Immunology and immunopathogenesis of dengue disease.

Authors:  Alan L Rothman
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

6.  A ligand-binding pocket in the dengue virus envelope glycoprotein.

Authors:  Yorgo Modis; Steven Ogata; David Clements; Stephen C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-20       Impact factor: 11.205

7.  Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical.

Authors:  Sujan Shresta; Jennifer L Kyle; Heidi M Snider; Manasa Basavapatna; P Robert Beatty; Eva Harris
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  Analysis of recombinant dengue virus polypeptides for dengue diagnosis and evaluation of the humoral immune response.

Authors:  Flavia Barreto dos Santos; Marize Pereira Miagostovich; Rita Maria Ribeiro Nogueira; Hermann Goncalves Schatzmayr; Lee W Riley; Eva Harris
Journal:  Am J Trop Med Hyg       Date:  2004-08       Impact factor: 2.345

9.  Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever.

Authors:  Juthathip Mongkolsapaya; Wanwisa Dejnirattisai; Xiao-ning Xu; Sirijitt Vasanawathana; Nattaya Tangthawornchaikul; Aroonrung Chairunsri; Siraporn Sawasdivorn; Thaneeya Duangchinda; Tao Dong; Sarah Rowland-Jones; Pa-thai Yenchitsomanus; Andrew McMichael; Prida Malasit; Gavin Screaton
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

10.  Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice.

Authors:  Sujan Shresta; Jennifer L Kyle; P Robert Beatty; Eva Harris
Journal:  Virology       Date:  2004-02-20       Impact factor: 3.616

View more
  177 in total

1.  Inhibition of dengue virus RNA synthesis by an adenosine nucleoside.

Authors:  Yen-Liang Chen; Zheng Yin; Jeyaraj Duraiswamy; Wouter Schul; Chin Chin Lim; Boping Liu; Hao Ying Xu; Min Qing; Andy Yip; Gang Wang; Wai Ling Chan; Hui Pen Tan; Melissa Lo; Sarah Liung; Ravinder Reddy Kondreddi; Ranga Rao; Helen Gu; Handan He; Thomas H Keller; Pei-Yong Shi
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease.

Authors:  Vanessa V Sarathy; Mellodee White; Li Li; Summer R Gorder; Richard B Pyles; Gerald A Campbell; Gregg N Milligan; Nigel Bourne; Alan D T Barrett
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

3.  Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells.

Authors:  Simona Zompi; Brian H Santich; P Robert Beatty; Eva Harris
Journal:  J Immunol       Date:  2011-11-30       Impact factor: 5.422

4.  Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo.

Authors:  Katherine L Williams; Wahala M P B Wahala; Susana Orozco; Aravinda M de Silva; Eva Harris
Journal:  Virology       Date:  2012-04-25       Impact factor: 3.616

5.  The necessity and quandaries of dengue vaccine development.

Authors:  Stephen J Thomas
Journal:  J Infect Dis       Date:  2011-02-01       Impact factor: 5.226

6.  Mouse STAT2 restricts early dengue virus replication.

Authors:  Joseph Ashour; Juliet Morrison; Maudry Laurent-Rolle; Alan Belicha-Villanueva; Courtney Ray Plumlee; Dabeiba Bernal-Rubio; Katherine L Williams; Eva Harris; Ana Fernandez-Sesma; Christian Schindler; Adolfo García-Sastre
Journal:  Cell Host Microbe       Date:  2010-11-18       Impact factor: 21.023

7.  Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment.

Authors:  Szu-Yuan Pu; Fei Xiao; Stanford Schor; Elena Bekerman; Fabio Zanini; Rina Barouch-Bentov; Claude M Nagamine; Shirit Einav
Journal:  Antiviral Res       Date:  2018-05-16       Impact factor: 5.970

8.  Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2.

Authors:  Ryosuke Suzuki; Evandro R Winkelmann; Peter W Mason
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

9.  The roles of IRF-3 and IRF-7 in innate antiviral immunity against dengue virus.

Authors:  Hui-Wen Chen; Kevin King; Jui Tu; Marisa Sanchez; Andrew D Luster; Sujan Shresta
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

10.  Synergism between the tyrosine kinase inhibitor sunitinib and Anti-TNF antibody protects against lethal dengue infection.

Authors:  Emilie Branche; William Weihao Tang; Karla M Viramontes; Matthew Perry Young; Nicholas Sheets; Yunichel Joo; Anh-Viet T Nguyen; Sujan Shresta
Journal:  Antiviral Res       Date:  2018-07-30       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.